Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -36.95% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
SPTX Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-36.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-3.62%
vs the sector median at left
Seaport Therapeutics, Inc. Common Stock
Market Cap
$929.83M
Return on Invested Capital (ROIC)
-36.95%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$934.79M
Return on Invested Capital (ROIC)
-67.13%
TTM Avg
-38.55%
3Y Avg
-37.38%
5Y Avg
-31.65%
Market Cap
$923.53M
Return on Invested Capital (ROIC)
-46.54%
TTM Avg
-25.88%
3Y Avg
-39.60%
5Y Avg
-39.60%
Market Cap
$921.06M
Return on Invested Capital (ROIC)
-50.77%
TTM Avg
-47.91%
3Y Avg
-50.09%
5Y Avg
-281.80%
Market Cap
$914.73M
Return on Invested Capital (ROIC)
4.96%
TTM Avg
4.19%
3Y Avg
3.59%
5Y Avg
3.20%
Market Cap
$952.91M
Return on Invested Capital (ROIC)
-82.30%
TTM Avg
-52.55%
3Y Avg
-42.51%
5Y Avg
-41.57%
Market Cap
$953.81M
Return on Invested Capital (ROIC)
-16.54%
TTM Avg
-24.45%
3Y Avg
-23.43%
5Y Avg
-23.43%
Market Cap
$887.99M
Return on Invested Capital (ROIC)
-25.25%
TTM Avg
-75.69%
3Y Avg
-67.13%
5Y Avg
-61.15%
Market Cap
$887.50M
Return on Invested Capital (ROIC)
11.37%
TTM Avg
4.29%
3Y Avg
-4.73%
5Y Avg
-2.12%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $929.83M | -36.95% | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | -67.13% | -38.55% | -37.38% | -31.65% |
| CeriBell, Inc. (CBLL)vs › | $923.53M | -46.54% | -25.88% | -39.60% | -39.60% |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | -50.77% | -47.91% | -50.09% | -281.80% |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 4.96% | 4.19% | 3.59% | 3.20% |
| Savara Inc. (SVRA)vs › | $952.91M | -82.30% | -52.55% | -42.51% | -41.57% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -16.54% | -24.45% | -23.43% | -23.43% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | -25.25% | -75.69% | -67.13% | -61.15% |
| Bioventus Inc. (BVS)vs › | $887.50M | 11.37% | 4.29% | -4.73% | -2.12% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 1.35% | -1.75% | 1.09% | 1.96% |
ROIC
-37.0%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -36.95% |
